ResearcherTaipei Medical University HospitalActive in the last 2 years
Shih‐Yi Huang
Matched on ORCID iD 0000-0003-2914-5513; OpenAlex author ID A5037307614. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 6
2021: 3 papers · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper
Papers 6
- Author Correction: Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mutant pancreatic cancer cells Co-author DOI 10.1038/s12276-025-01437-w↗
- Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mutant pancreatic cancer cells. Co-author DOI 10.1038/s12276-024-01300-4↗
- The Role of Dicer Phosphorylation in Gemcitabine Resistance of Pancreatic Cancer. Last author DOI 10.3390/ijms252111797↗
- A case-control study in Taiwanese cohort and meta-analysis of serum ferritin in pancreatic cancer. Co-author DOI 10.1038/s41598-021-00650-7↗
- Eicosapentaenoic Acid Inhibits KRAS Mutant Pancreatic Cancer Cell Growth by Suppressing Hepassocin Expression and STAT3 Phosphorylation. Last author DOI 10.3390/biom11030370↗
- Betulinic Acid Affects the Energy-Related Proteomic Profiling in Pancreatic Ductal Adenocarcinoma Cells. Last author DOI 10.3390/molecules26092482↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ching‐Feng Chiu · 6 shared papers, 2021–2025 · strength 1.07
- Paper The Role of Dicer Phosphorylation in Gemcitabine Resistance of Pancreatic Cancer. DOI 10.3390/ijms252111797↗
- Paper Author Correction: Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mu… DOI 10.1038/s12276-025-01437-w↗
- Paper Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mutant pancreatic can… DOI 10.1038/s12276-024-01300-4↗
- Yen‐Hao Su · 4 shared papers, 2021–2025 · strength 0.79
- Paper The Role of Dicer Phosphorylation in Gemcitabine Resistance of Pancreatic Cancer. DOI 10.3390/ijms252111797↗
- Paper Author Correction: Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mu… DOI 10.1038/s12276-025-01437-w↗
- Paper Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mutant pancreatic can… DOI 10.1038/s12276-024-01300-4↗
- Ji Min Park · 4 shared papers, 2021–2025 · strength 0.67
- Paper Author Correction: Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mu… DOI 10.1038/s12276-025-01437-w↗
- Paper Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mutant pancreatic can… DOI 10.1038/s12276-024-01300-4↗
- Paper A case-control study in Taiwanese cohort and meta-analysis of serum ferritin in pancreatic cancer. DOI 10.1038/s41598-021-00650-7↗
- Tze‐Sing Huang · 2 shared papers, 2024–2025 · strength 0.39
- Paper Author Correction: Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mu… DOI 10.1038/s12276-025-01437-w↗
- Paper Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mutant pancreatic can… DOI 10.1038/s12276-024-01300-4↗
- Chi-Shuan Fan · 2 shared papers, 2024–2025 · strength 0.39
- Paper Author Correction: Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mu… DOI 10.1038/s12276-025-01437-w↗
- Paper Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mutant pancreatic can… DOI 10.1038/s12276-024-01300-4↗
- Wun‐Shaing Wayne Chang · 2 shared papers, 2024–2025 · strength 0.39
- Paper Author Correction: Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mu… DOI 10.1038/s12276-025-01437-w↗
- Paper Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mutant pancreatic can… DOI 10.1038/s12276-024-01300-4↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.